Comparative Pharmacology
Head-to-head clinical analysis: ACTOPLUS MET XR versus ROSIGLITAZONE MALEATE AND METFORMIN HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACTOPLUS MET XR versus ROSIGLITAZONE MALEATE AND METFORMIN HYDROCHLORIDE.
ACTOPLUS MET XR vs ROSIGLITAZONE MALEATE AND METFORMIN HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ACTOPLUS MET XR combines pioglitazone, a thiazolidinedione that improves insulin sensitivity by activating PPAR-γ, and metformin, a biguanide that decreases hepatic glucose production and improves peripheral glucose uptake.
Rosiglitazone is a thiazolidinedione that activates peroxisome proliferator-activated receptor gamma (PPARγ), increasing insulin sensitivity in adipose tissue, muscle, and liver. Metformin is a biguanide that decreases hepatic glucose production, decreases intestinal glucose absorption, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.
Initial dose: 15 mg pioglitazone/500 mg metformin hydrochloride extended-release orally once daily with evening meal. Titrate based on glycemic response, maximum dose 45 mg pioglitazone/2000 mg metformin hydrochloride extended-release per day.
Oral, initial: rosiglitazone 2 mg plus metformin 500 mg twice daily; maximum: rosiglitazone 8 mg plus metformin 2000 mg per day (divided twice daily).
None Documented
None Documented
Pioglitazone: terminal half-life 3-7 hours (parent), 16-24 hours (active metabolites); clinical effect sustained due to metabolites. Metformin: terminal half-life 6.2 hours (plasma), elimination prolonged in renal impairment (creatinine clearance <60 mL/min).
Metformin: 4-8.7 h (elimination), prolonged in renal impairment; Rosiglitazone: 3-4 h (terminal), slightly longer in hepatic impairment.
Pioglitazone: predominantly hepatic metabolism, 15-30% excreted in urine as metabolites, ~20% in feces. Metformin: 90% renal excretion unchanged via glomerular filtration and tubular secretion.
Metformin: 90% renal unchanged via tubular secretion; Rosiglitazone: 64% renal (metabolites), 23% fecal. Combined: minimal biliary excretion.
Category C
Category A/B
Thiazolidinedione/Biguanide Combination
Thiazolidinedione